YS Biopharma Co., Ltd. (NASDAQ:YS – Free Report) – Research analysts at Diamond Equity lowered their FY2024 earnings per share (EPS) estimates for YS Biopharma in a research report issued to clients and investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now anticipates that the company will earn ($0.45) per share for the year, down from their prior forecast of ($0.24). The consensus estimate for YS Biopharma’s current full-year earnings is ($0.45) per share. Diamond Equity also issued estimates for YS Biopharma’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.
YS Biopharma Stock Performance
NASDAQ:YS opened at $0.80 on Thursday. YS Biopharma has a one year low of $0.35 and a one year high of $1.97. The company has a quick ratio of 1.09, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average price of $0.67 and a 200 day moving average price of $0.58.
Institutional Investors Weigh In On YS Biopharma
YS Biopharma Company Profile
YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
Further Reading
- Five stocks we like better than YS Biopharma
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Stocks Leading the U.S. Agriculture Comeback
- Stock Analyst Ratings and Canadian Analyst Ratings
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Consumer Discretionary Stocks Explained
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for YS Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YS Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.